Long Term Results of Single-Fraction Carbon-Ion Radiotherapy for Non-small Cell Lung Cancer.
carcinoma
dose fractionation
heavy ion radiotherapy
non-small cell lung
radiation
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 Dec 2020
31 Dec 2020
Historique:
received:
18
11
2020
revised:
24
12
2020
accepted:
28
12
2020
entrez:
5
1
2021
pubmed:
6
1
2021
medline:
6
1
2021
Statut:
epublish
Résumé
The purpose of the present study was to evaluate the efficacy and safety of single-fraction carbon-ion radiotherapy (CIRT) in patients with non-small cell lung cancer. Patients with histologically confirmed non-small cell lung cancer, stage T1-2N0M0, and treated with single-fraction CIRT (50Gy (relative biological effectiveness)) between June 2011 and April 2016 were identified in our database and retrospectively analyzed. Toxicity was evaluated using the Common Terminology Criteria for Adverse Events version 4.0. The study included 57 patients, 22 (38.6%) of whom had inoperable cancer. The median age was 75 years (range: 42-94 years), and the median follow-up time was 61 months (range: 6-97 months). The 3- and 5-year overall survival rates were 91.2% and 81.7%, respectively. All survivors were followed up for more than three years. The 3- and 5-year local control rates were 96.4% and 91.8%, respectively. No case of ≥ grade 2 pneumonitis was recorded. This study suggests that single-fraction CIRT for T1-2N0M0 non-small cell lung cancer patients is feasible and can be considered as one of the treatment choices, especially in medically inoperable patients.
Sections du résumé
BACKGROUND
BACKGROUND
The purpose of the present study was to evaluate the efficacy and safety of single-fraction carbon-ion radiotherapy (CIRT) in patients with non-small cell lung cancer.
METHODS
METHODS
Patients with histologically confirmed non-small cell lung cancer, stage T1-2N0M0, and treated with single-fraction CIRT (50Gy (relative biological effectiveness)) between June 2011 and April 2016 were identified in our database and retrospectively analyzed. Toxicity was evaluated using the Common Terminology Criteria for Adverse Events version 4.0.
RESULTS
RESULTS
The study included 57 patients, 22 (38.6%) of whom had inoperable cancer. The median age was 75 years (range: 42-94 years), and the median follow-up time was 61 months (range: 6-97 months). The 3- and 5-year overall survival rates were 91.2% and 81.7%, respectively. All survivors were followed up for more than three years. The 3- and 5-year local control rates were 96.4% and 91.8%, respectively. No case of ≥ grade 2 pneumonitis was recorded.
CONCLUSIONS
CONCLUSIONS
This study suggests that single-fraction CIRT for T1-2N0M0 non-small cell lung cancer patients is feasible and can be considered as one of the treatment choices, especially in medically inoperable patients.
Identifiants
pubmed: 33396455
pii: cancers13010112
doi: 10.3390/cancers13010112
pmc: PMC7795673
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Anticancer Res. 2014 Sep;34(9):5099-104
pubmed: 25202098
Ther Adv Med Oncol. 2018 Jul 13;10:1758835918787989
pubmed: 30023008
Lancet Oncol. 2015 Jun;16(6):630-7
pubmed: 25981812
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):457-62
pubmed: 21035956
J Clin Oncol. 2007 Mar 10;25(8):953-64
pubmed: 17350944
J Thorac Oncol. 2010 Dec;5(12):1999-2002
pubmed: 21102261
Cancer. 2010 May 15;116(10):2476-85
pubmed: 20225229
Radiother Oncol. 2014 Aug;112(2):256-61
pubmed: 25108807
Radiother Oncol. 2017 Oct;125(1):31-35
pubmed: 28784437
Biomed Res Int. 2014;2014:727962
pubmed: 25295269
Lancet. 2017 Jan 21;389(10066):299-311
pubmed: 27574741
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Ann Thorac Surg. 2016 May;101(5):1850-5
pubmed: 27041452
Chest. 2007 Jul;132(1):193-9
pubmed: 17505036
Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):750-8
pubmed: 17293232
Ann Thorac Cardiovasc Surg. 2011;17(5):469-80
pubmed: 21881356
Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):989-96
pubmed: 26581137
Eur J Cardiothorac Surg. 2016 May;49(5):1503-9
pubmed: 26468271
Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1427-31
pubmed: 16169670
Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):82-89
pubmed: 31580927
Radiographics. 2011 Jan-Feb;31(1):215-38
pubmed: 21257943
Radiother Oncol. 2003 Feb;66(2):127-40
pubmed: 12648784
J Thorac Oncol. 2017 Apr;12(4):673-680
pubmed: 28007628
Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1077-1084
pubmed: 30513377
J Thorac Oncol. 2019 Feb;14(2):212-222
pubmed: 30316011
J Thorac Oncol. 2007 Oct;2(10):916-26
pubmed: 17909354
Cancer Med. 2019 Nov;8(15):6644-6650
pubmed: 31532584
Am J Clin Oncol. 2020 Aug;43(8):575-581
pubmed: 32554982
Thorac Cancer. 2016 Jul;7(4):442-51
pubmed: 27385987